Ranbaxy Laboratories has made two fresh filings of its anti-retroviral (ARV) agents with the World Health Organisation (WHO) for approval, taking the total number of filings submitted to WHO to five.This was announced in a release issued by Ranbaxy to the BSE today."Ranbaxy has also filed one more ARV with the USFDA under the expedited review process for the US President's Emergency Programme For Aids Relief (PEPFAR), thus taking the total number of ARV filings with the USFDA to 4," the release said.Brian W. Tempest, CEO and MD of Ranbaxy, said: "Ranbaxy remains committed towards refiling its ARVs with WHO and USFDA (under the PEPFAR programme). We expect most of our range of HIV medicines to be filed with WHO and USFDA by this summer."
